Optimer Looking At Prophylaxis As Next Frontier For C. Difficile Agent Dificid
Executive Summary
Optimer's next step, having garnered the expected FDA approval of its Clostridium difficile antibiotic Dificid (fidaxomicin), will be to consider prophylaxis as a possible road to an expanded market for the macrolide antibiotic.
You may also be interested in...
Optimer's Early Sales Of Dificid Topping Analyst Projections
The anti-clostridial antibiotic, approved by FDA in May, is seeing rapid early adoption by hospital formularies.
Optimer's Early Sales Of Dificid Topping Analyst Projections
The anti-clostridial antibiotic, approved by FDA in May, is seeing rapid early adoption by hospital formularies.
Optimer's Fidaxomicin Among Three NMEs Given Positive Review By Europe's Regulators
EU's scientific advisory panel also recommends approval for Takeda's azilsartan and Tibotec's rilpivirine, and grants positive opinions on new indications for Bayer/Johnson & Johnson's rivaroxaban and Alexion's eculizumab.